doi: 10.3389/fphar.2025.1602976 Received 30 March 2025 Revised 13 November 2025 Accepted 14 November 2025 Published 19 December 2025 Volume 16 - 2025 Edited by Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa Reviewed by Kacper Nijakowski, Poznan University of Medical Sciences, Poland Miriam Njoki Karinja, Science for Africa Foundation, Kenya Updates Copyright 2025 Mazur, Ndokaj, Salerno, Vallone, Ardan, Bietolini, Carrouel, Wilk, Sarig, Ottolenghi and Bourgeois
Utilisation des vitamines B6 et B12 dans le traitement du cancer Concernant lutilisation des vitamines B6 et B12 dans le traitement du cancer, la plupart des tudes se sont concentres sur le lien entre ces vitamines et le risque de certains types de cancer
Regulatory Status AOD-9604 is not FDA-approved for any medical use and is listed by the FDA as a bulk drug substance that may present safety risks. Clinical development was halted after Phase IIb trials failed to meet efficacy endpoints. Summary AOD-9604 is a synthetic analog of the HGH 177191 fragment developed for fat-metabolism research
Its applications continue to expand within functional and regenerative medicine
Concentration accuracy is harder than it looks The 0.9% benzyl alcohol target is a narrow window with consequences on both sides: Too little benzyl alcohol (below ~0.5%) and the bacteriostatic effect weakens significantly, allowing bacterial growth in the multi-dose vial during the 28-day use window Too much benzyl alcohol (above ~2%) and tissue toxicity becomes a concern published research has documented injection site irritation, tissue damage, and in extreme concentrations, systemic toxicity from benzyl alcohol exposure For a 30 mL batch, the target benzyl alcohol volume is 0.27 mL roughly five drops from a standard dropper
They are running an uncontrolled experiment on their own tissue
